Scott T. Rottinghaus, Chief Medical Officer of Enanta Pharmaceuticals Inc., filed a statement of changes in beneficial ownership on August 10, 2026, reporting a disposition of common stock on August 8, 2026, tied to the settlement of a restricted stock unit award.

Key Highlights

  • Reporting person: Scott T. Rottinghaus, Chief Medical Officer of Enanta Pharmaceuticals Inc. (NASDAQ: ENTA)
  • Transaction date: August 8, 2026, with the filing submitted on August 10, 2026
  • Shares forfeited: 1,467 shares of ENTA common stock disposed of (transaction code F) at $13.34 per share
  • Purpose: Shares were forfeited to cover withholding taxes upon settlement of a portion of the restricted stock unit award granted on August 8, 2022
  • Resulting ownership: Rottinghaus directly holds 23,787 shares of Enanta common stock following the transaction
  • Filing scope: No derivative securities transactions were reported in Table II

RSU Settlement Triggers Tax-Withholding Share Forfeiture by Enanta CMO

According to the filing, Scott T. Rottinghaus, who serves as Chief Medical Officer of Enanta Pharmaceuticals Inc., a biopharmaceutical company based in Watertown, Massachusetts, disposed of 1,467 shares of common stock on August 8, 2026. The transaction was coded "F," indicating shares withheld or forfeited to cover tax obligations, rather than an open-market sale. The filing states the shares were forfeited "to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on August 8, 2022."

The price recorded for the disposition was $13.34 per share. Following this transaction, Rottinghaus directly holds 23,787 shares of Enanta common stock, as reported in Table I of the filing. The filing was signed by Matthew Kowalsky as attorney-in-fact on August 10, 2026, and was filed by one reporting person. No derivative securities, such as options or warrants, were reported as acquired or disposed of in connection with this filing.

What Was Disclosed

The filing reported a single disposition of 1,467 shares of Enanta Pharmaceuticals common stock by Chief Medical Officer Scott T. Rottinghaus on August 8, 2026, at $13.34 per share, solely to satisfy tax withholding obligations upon RSU settlement. Post-transaction direct ownership stands at 23,787 shares.